Altimmune granted fast track designation by fda for pemvidutide for the treatment of non-alcoholic steatohepatitis (nash)

Gaithersburg, md., oct. 26, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that the u.s. food and drug administration (fda) has granted fast track designation to its clinical program investigating pemvidutide for the treatment of nash.
ALT Ratings Summary
ALT Quant Ranking